Brain Hemorrhages最新文献

{"title":"Premorbid long-term statin use can reduce the risk of hemorrhagic transformation after ischemic stroke","authors":"Zhixin Li , Riguge Su , Yu Zhang , Duanlu Hou , Basak Caner , Wei Yan , Xiaobo Yang , Heling Chu , Yuping Tang","doi":"10.1016/j.hest.2024.12.001","DOIUrl":"10.1016/j.hest.2024.12.001","url":null,"abstract":"<div><h3>Objective</h3><div>Hemorrhagic transformation (HT) of cerebral infarction is considered as one of the most serious complications. Increasing evidence show that statin use might reduce the neuroinflammation and even improve clinical prognosis of stroke patients. However, there is not enough evidence that premorbid statin use may affect the risk of hemorrhagic transformation in stroke patients. The aim of our study was to investigate the role of premorbid long-term statin use in HT after acute ischemic stroke.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed ischemic stroke patients in Huashan Hospital from 1 January 2012 to 31 December 2022 based on hospital electronic case records. Since thrombolysis or thrombectomy might interfere with the effect of statin use we excluded patients who received thrombolysis or thrombectomy treatment. A matched case-control study was conducted for reducing the impact of various confounding factors. The independent roles of statin use and serum lipids in HT was evaluated by binary logistic regression analysis.</div></div><div><h3>Results</h3><div>A total of 254 ischemic stroke patients met the inclusion criteria and have been matched at 1:1 ratio, according age (± 5 years), admission NIHSS (± 3 scores), prior antiplatelets and anticoagulation therapy and previous stroke history. The patients without HT were regarded as control group. The percentage of HT was significantly lower in patients with premorbid long-term statin use (22.1 % vs. 41.7 %, p = 0.001). The incidence rate of diabetes mellitus and symptomatic deterioration (NIHSS increase ≥ 4) was higher in patients with HT. There were 18 patients having intracerebral hemorrhage before any reperfusion treatment. They had lower level of LDL-C (1.76 (1.73, 2.26) vs 2.72 (2.28, 3.09), p < 0.001) and were prone to previously take statins (55.6 % vs 16.5 %,p < 0.001). However, ECASS classification and all the outcome scores did not present any statistical difference in our study. In logistic regression analysis DM (OR = 2.001, 95 %CI 1.124–3.563, <em>p</em> = 0.018), increased levels of LDC-C (OR = 0.334, 95 %CI 0.172–0.649), <em>p</em> = 0.001) and HDL-C (OR = 13.303, 95 %CI 2.050–86.328, p = 0.001) were independent risk factors in occurrence of HT in patients with ischemic stroke, while premorbid statin use (OR = 0.269, 95 %CI 0.117–0.615, p = 0.002) could still be regarded as a protective factor in preventing intracranial hemorrhage after cerebral infarction. Additionally, lower level of LDL-C was also an independent risk factor in spontaneous HT after cerebral infarction (OR = 45.45, 95 %CI 5.62–333.33, p < 0.001), regardless of statin use.</div></div><div><h3>Conclusion</h3><div>Premorbid long-term statin use plays a protective role in the HT after cerebral infarction. However, low serum LDL-C and high HDL-C might be independent risk factors in the occurrence of HT irrespective of statin use. The previous statin uses and serum li","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 3","pages":"Pages 95-102"},"PeriodicalIF":1.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of ruptured basilar artery perforator aneurysm undetected on initial angiogram and unruptured anterior cerebral artery saccular aneurysm: Case report and literature review","authors":"Hideki Nakajima ,&nbsp;Yu Sato ,&nbsp;Tetsushi Yago ,&nbsp;Kazuhiko Tsuda ,&nbsp;Hidenori Suzuki","doi":"10.1016/j.hest.2024.07.008","DOIUrl":"10.1016/j.hest.2024.07.008","url":null,"abstract":"<div><h3>Objective</h3><div>Ruptured basilar artery perforator aneurysm (BAPA) is a rare cause of subarachnoid hemorrhage (SAH) and is difficult to diagnose.</div></div><div><h3>Case presentation</h3><div>A 60-year-old male was rushed to our hospital due to severe headache. Computed tomography (CT) showed diffuse SAH, and 3-dimensional CT angiography (CTA) showed a saccular aneurysm in the left anterior cerebral artery (ACA), which was treated with clipping. However, intraoperative findings showed little SAH around the aneurysm and neither a rupture point nor a white thrombus on the aneurysm. Postoperative CT showed a marked decrease in SAH in the prepontine cistern, and digital subtraction angiography (DSA) showed disappearance of the ACA aneurysm and no other lesions. SAH in the prepontine cistern re-increased on CT on the 6th postoperative day, when CTA failed to show the cause. On the 12th postoperative day, CT showed further increased SAH in the prepontine cistern, and DSA revealed a BAPA. Stent-assisted coil embolization was planned at the chronic phase, but the patient went into cardiac arrest the next day, presumably due to a third re-rupture of the BAPA.</div></div><div><h3>Conclusion</h3><div>The coexistence of a ruptured BAPA and an unruptured saccular aneurysm is extremely challenging in terms of both diagnosis and treatment strategy.</div></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 3","pages":"Pages 138-141"},"PeriodicalIF":1.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141853799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing brain injury treatment and neuroprotection with ligustilide: Mechanisms and therapeutic potential","authors":"Qiaoqiao Xu,&nbsp;Wei Mei","doi":"10.1016/j.hest.2025.01.003","DOIUrl":"10.1016/j.hest.2025.01.003","url":null,"abstract":"<div><div>Brain injury is one of the leading causes of death and disability worldwide, attributable to diverse etiologies such as trauma, hypoxia, stroke, infection, or neurodegenerative diseases. Due to the complex pathophysiology, high prevalence, and limited therapeutic options, brain injury poses significant healthcare challenges. Current treatment for brain injury involves a combination of medical interventions, surgery, and rehabilitation therapies. Ligustilide, a bioactive component purified from traditional Chinese medicinal herb, has been studied as a promising candidate for neuroprotection. In this review, we summarize current research to understand the mechanisms underlying ligustilide neuroprotective activities and assess its therapeutic potential in treating brain injuries.</div></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 3","pages":"Pages 121-127"},"PeriodicalIF":1.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stromal vascular fraction cell therapy: A promising therapeutic method for intracerebral hemorrhage","authors":"Ilgiz Gareev ,&nbsp;Ozal Beylerli ,&nbsp;Albert Sufianov ,&nbsp;Valentin Pavlov ,&nbsp;Huaizhang Shi","doi":"10.1016/j.hest.2025.01.002","DOIUrl":"10.1016/j.hest.2025.01.002","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Intracerebral hemorrhage (ICH) is one of the most devastating and life-threatening forms of stroke, characterized by bleeding within the brain parenchyma. The condition is associated with a high mortality rate and significant long-term disabilities among survivors, underscoring the urgent need for innovative therapeutic strategies that go beyond managing symptoms to actively promote brain repair and functional recovery. Current treatment options are largely limited to supportive care, including surgical interventions to alleviate intracranial pressure and management of underlying risk factors such as hypertension. These approaches, however, fail to address the extensive neurological damage caused by ICH. Emerging evidence highlights the potential of stromal vascular fraction (SVF) cell therapy as a novel regenerative treatment for ICH. SVF, derived from adipose tissue through enzymatic digestion, is a heterogeneous mixture of cells, including mesenchymal stem cells (MSCs), endothelial cells, pericytes, immune cells, and progenitor cells. This cellular composition contributes synergistically to the repair and regeneration of damaged tissues. The mechanisms of action of SVF encompass inflammation modulation, neuroprotection, angiogenesis, and immunomodulation. MSCs within SVF release anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), reducing secondary injury caused by excessive inflammation. Endothelial cells and pericytes promote the formation of new blood vessels, restoring oxygen and nutrient supply to ischemic regions. Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) further support neuronal survival and repair of neural circuits. Preclinical studies in animal models have consistently demonstrated the efficacy of SVF therapy, including reductions in brain edema, oxidative stress, and inflammatory cytokines, alongside improvements in angiogenesis, neuronal survival, and functional recovery. Early-phase clinical trials and case studies provide preliminary evidence of safety, feasibility, and potential therapeutic benefits in human patients with acute and chronic ICH. However, significant challenges remain, including the variability in SVF composition, optimal delivery methods, timing of intervention, and long-term safety considerations. This review comprehensively examines the biological properties of SVF, the mechanisms underlying its therapeutic effects, and the preclinical and clinical evidence supporting its use in ICH. Additionally, it explores future directions, including the development of standardized protocols, optimization of delivery techniques, integration with combination therapies, and the potential for personalized medicine approaches. As ongoing research and clinical trials refine these strategies, SVF therapy holds transformative potential to revolutionize ICH treatment by addressing its complex pathophysiology and i","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 3","pages":"Pages 110-120"},"PeriodicalIF":1.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Progressive Frontier of Aneurysmal subarachnoid Hemorrhage: Diagnosis and treatment Advances","authors":"Yi Luo ,&nbsp;Maokun Li","doi":"10.1016/j.hest.2024.09.001","DOIUrl":"10.1016/j.hest.2024.09.001","url":null,"abstract":"<div><div>Aneurysmal subarachnoid hemorrhage affects 6 to 9 out of every 100,000 people annually, with a mortality rate of 35%. Many people suffer from long-term disabilities, often associated with cognitive impairment. Aneurysmal subarachnoid hemorrhage requires timely stabilization, diagnosis, and treatment. The typical manifestation of severe headaches is common. There are also a wide range of symptoms, including mild pain and coma. We delve into the importance of the field, the significance of ongoing research, and the advancements made in diagnosing and treating this condition, aiming to provide a comprehensive overview.</div></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 3","pages":"Pages 128-137"},"PeriodicalIF":1.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of 3D printing technology-assisted neuroendoscopic surgery for hypertensive intracerebral hemorrhage in primary hospitals","authors":"Jiandong Wu ,&nbsp;Yuhui Gong ,&nbsp;Jinhong Qian,&nbsp;Xiaoyu Tang,&nbsp;Peng Deng,&nbsp;Haolong Ding,&nbsp;Zhiliang Ding,&nbsp;Mian Ma","doi":"10.1016/j.hest.2024.08.002","DOIUrl":"10.1016/j.hest.2024.08.002","url":null,"abstract":"<div><h3>Objective</h3><div>We aimed to investigate the clinical effectiveness of integrating 3D-printing technology with neuroendoscopy for treating hypertensive intracerebral hemorrhage (HICH).</div></div><div><h3>Methods</h3><div>Between November 2020 and November 2023, a total of 105 HICH cases were selected and categorized into the conventional surgery group and the neuroendoscopic surgery. General data, Glasgow Coma Scale (GCS), National institutes of health neurological impairment score (NIHSS), preoperative hematoma volume, intracerebral parenchymal and intraventricular hematoma (IVH) clearance rates, Modified Graeb Scale (mGS), postoperative rebleeding rate, intracranial infection, and Modified Rankin Scale (mRS) were collected to assess the therapeutic effectiveness.</div></div><div><h3>Results</h3><div>There were no significant statistical differences in gender, age, preoperative GCS scores, NIHSS or hematoma volume between the neuroendoscopic surgery and conventional surgery group. The postoperative results indicated that the clearance rate of intracerebral parenchymal and IVH in neuroendoscopic surgery group was notably higher than the conventional surgery group. The neuroendoscopic surgery group achieved superior outcomes in terms of bone flap area, operation time, extubation time, and average hospital stay compared to the conventional surgery group (P &lt; 0.05). Following a 3-month follow-up, there was no significant difference in the mRS and NIHSS between the two groups. However, when the patients with IVH (mGS≥10) indicated better postoperative outcomes in the neuroendoscopic surgery group (P &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>The integration of neuroendoscopic minimally invasive surgery with 3D-printing technology for treating HICH demonstrated high efficacy for removing intracerebral and IVH. This approach incurred less trauma compared to traditional craniectomy surgery, affording shortened surgical and hospitalization durations. Consequently, it appears to be a highly efficacious method for treating HICH, particularly in cases involving IVH.</div></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 3","pages":"Pages 103-109"},"PeriodicalIF":1.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of recovery and death within 1–6 months of spontaneous cerebellar hemorrhage undergoing suboccipital craniotomy","authors":"Phuong Xuan Nguyen ,&nbsp;Tung Duc Nguyen ,&nbsp;Cuong Manh Tran ,&nbsp;Tuan Cong Duong ,&nbsp;Ha Thi-Ngoc Doan ,&nbsp;Yen Trong Nguyen","doi":"10.1016/j.hest.2024.05.005","DOIUrl":"10.1016/j.hest.2024.05.005","url":null,"abstract":"<div><h3>Objective</h3><div>Suboccipital craniotomy is a considerable surgical approach for large spontaneous cerebellar hemorrhage, but its prognostic has not been comprehensively addressed. This study aims to report the surgical outcomes and factors related to the prognosis of recovery and death within 1–6 months of patients with spontaneous cerebellar hemorrhage.</div></div><div><h3>Methods</h3><div>We retrospectively studied 37 patients who underwent craniotomy due to spontaneous cerebellar hemorrhage from January 2019 to April 2022.</div></div><div><h3>Results</h3><div>The disease occurs at a mean age of 62.86 years old, with a male/female ratio of 4.26/1. Hemorrhage is mainly in the cerebellar hemisphere. Hospital stays averaged 13.32 days, with significant reductions in hematoma diameter and volume after surgery. The hospital mortality rate was 5.41 %, increasing to 45.95 % at 1 month post-discharge. Prognostic factors for death within 1 month include low Glasgow score, small hematoma diameter, and low hematoma volume. Factors associated with recovery include young age, absence of ventricle hemorrhage, and high Glasgow score.</div></div><div><h3>Conclusions</h3><div>Suboccipital craniotomy demonstrates a high efficacy in resolving hematomas with decreased complication rates, lower mortality, and improved patient recovery outcomes. Optimal surgical outcomes would be achieved with early intervention, particularly in younger patients.</div></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 2","pages":"Pages 76-80"},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracranial pressure monitoring and minimally invasive surgery for intracerebral hemorrhage: Current status, challenges, and future","authors":"Ping Zhang ,&nbsp;Xinran Xu ,&nbsp;Chao Pan ,&nbsp;Yingxin Tang ,&nbsp;Wenjie Liu ,&nbsp;Zhouping Tang","doi":"10.1016/j.hest.2025.03.001","DOIUrl":"10.1016/j.hest.2025.03.001","url":null,"abstract":"<div><div>With the continuous advancement of medical technology, the treatment for intracerebral hemorrhage (ICH) has shifted from traditional open surgery to more precise minimally invasive surgery (MIS). This article will discuss the combination of intracranial pressure (ICP) monitoring and MIS in ICH management, as well as explore future development directions.</div></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 2","pages":"Pages 61-63"},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Step-down infusion of barbiturate improves neurofunction in a new rat model of rebleeding subarachnoid hemorrhage","authors":"Sosho Kajiwara ,&nbsp;Yu Hasegawa ,&nbsp;Kana Fujimori ,&nbsp;Motohiro Morioka","doi":"10.1016/j.hest.2024.07.001","DOIUrl":"10.1016/j.hest.2024.07.001","url":null,"abstract":"<div><h3>Objective</h3><div>Rebleeding from a ruptured aneurysm is a risk factor for fatal prognosis in subarachnoid hemorrhage (SAH). A novel barbiturate treatment, step-down infusion of barbiturate (sd-B), was previously developed; it showed beneficial effects on patients with severe traumatic brain injuries. The present study established a rebleeding SAH model in rats and evaluated the effect of sd-B.</div></div><div><h3>Methods</h3><div>Fifty male Sprague-Dawley rats were divided into sham-operation with distilled water, sham-operation with barbiturate, SAH-rebleeding with distilled water, and SAH-rebleeding with barbiturate groups. For posttreatment with sd-B, thiamylal was intraperitoneally administered at 3 mg/kg/h on days 0–1, 2 mg/kg/h on days 1–2, and 1 mg/kg/h on days 2–3 after SAH using osmotic minipumps. We monitored neurofunction and case fatality as the primary endpoints and evaluated brain injuries, including brain edema and cortical neuronal cell death, as the secondary endpoints</div></div><div><h3>Results</h3><div>Posttreatment with sd-B improved the modified Garcia test, reduced the brain water content, and inhibited the loss of neuronal cells and microglial expressions in the rat model.</div></div><div><h3>Conclusions</h3><div>Our results revealed that sd-B ameliorated neurofunction and brain injuries on the rebleeding SAH model, suggesting that the novel treatment is a good candidate drug for patients with SAH with rebleeding.</div></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 2","pages":"Pages 64-68"},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141701290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune cells in intracerebral hemorrhage","authors":"Irem Culha Taskin,&nbsp;Yao Yao","doi":"10.1016/j.hest.2025.02.001","DOIUrl":"10.1016/j.hest.2025.02.001","url":null,"abstract":"<div><div>Intracerebral hemorrhage (ICH), the deadliest form of stroke, is characterized by bleeding into brain parenchyma and formation of hematoma. Currently, there is no treatment available for ICH. Inflammatory response is a key pathology of ICH and plays a dual role in ICH---contributing to both secondary brain injury and recovery processes. This review discusses different types (both brain-resident and infiltrated) of immune cells and their functions during inflammation processes following ICH. Specifically, the temporal dynamics, polarization, and function of microglia/macrophages, neutrophils, lymphocytes, and astrocytes in ICH are summarized in a cell-specific manner. In addition, we also discuss key challenges and unanswered questions that need to be addressed in the future. A thorough understanding of the functions of different immune cells in ICH will provide a strong foundation for future studies and lead to the identification of novel cellular/molecular targets for therapeutic development.</div></div>","PeriodicalId":33969,"journal":{"name":"Brain Hemorrhages","volume":"6 2","pages":"Pages 86-94"},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}